European Psychiatry
March 1, 2023
J. Ramírez González, I. Fernández Márquez, Serafín González et al.
Introduction The use of hallucinogens has accompanied the human being throughout history. In the 1970s, studies focused on the therapeutic potential of hallucinogens were blocked due to their misuse in the young population. At present, psilocybin is re-emerging as the center of attention due to its possible therapeutic potential in different psychiatric pathologies such as depression, anxiety...
March 1, 2023
David Nutt, David Castle
4 citations
Abstract There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s and 1960s exploring the use of LSD and other psychedelics to treat a range of psychiatric illnesses as well as addictions. This research was shut down after prohibition of these drugs; however, the last decade has seen a major renewal of interest in...
Journal of Affective Disorders
February 3, 2023
Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al.
168 citations
Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.
Advances in Research
January 30, 2023
Jennings Hernandez
Roughly over 700 million individuals suffer from a mental illness globally. In the United States alone, over 45 million individuals are afflicted with a mental disorder at any given point in their lives. It is because of this that new methods of current therapies should be considered. To date, major depression disorder (MAD), anxiety, and post-traumatic stress disorder (PTSD) are treated with...
Journal of Psychedelic Studies
January 18, 2023
Benjamin R. Lewis, Kevin Byrne, John Hendrick et al.
22 citations
Abstract Background Psilocybin-assisted psychotherapy has demonstrated significant promise as a treatment for depression, anxiety, and existential distress associated with serious medical illness and has generally been employed on an individual basis, which presents challenges for scaling and resource availability. There are also compelling theoretical reasons to suggest that group-based...
AIDASCO Reviews
January 17, 2023
Dragana Marković, Eleonora Čapelja
2 citations
Major depressive disorder (MDD), also known as clinical depression, is a serious mental disorder and ranks first among psychiatric disorders that dominate the global disease burden. Recently, it was found that psilocybin, active compound derived from psychotropic mushrooms, can relieve depression symptoms rapidly and sustained benefits for several months. Beside MDD, psilocybin can alleviate...
Annals of Pharmacotherapy
January 12, 2023
C Michael White, Nissen Weisman, Joseph Dalo
18 citations
Objective: To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. Data Sources: PubMed search from inception to March 11, 2022, using the terms anxiety, depression, psychedelics, psilocybin, lysergic acid, methylenedioxymethamphetamine, or ayahuasca. Study Selection and Data Extraction: Studies assessing patients with cancer receiving...
IJS - International Journal of Sciences
2023
Fabiano F. Da Silva, Thaysa Adriane Costa Bernardo, Johny Ricarte Das Silva Rodrigues et al.
1 citation
Psilocybin in the treatment of generalized anxiety disorder has become a strong point since it can have important benefits in the treatment. The general objective of the present study is to review the literature on the use of psilocybin in the treatment of generalized anxiety disorder (GAD), alcoholism and smoking, in order to compile and analyze the available evidence on its efficacy, safety...
The Meducator
2023
Alam Mehrjerdi Zahra, Bhavana Soma
2 citations
Psilocybin is a naturally occurring compound present in numerous mushroom species characterised by its hallucinogenic and psychedelic effects. Although it has a negative reputation, psilocybin has demonstrated therapeutic potential for treating mental health disorders by allowing the brain to make new neural connections which help the neural pathways adapt and break out of certain cognitive...
Therapeutic Advances in Psychopharmacology
2023
Ricarda Evens, Tomislav Majić, Timo Torsten Schmidt et al.
49 citations
Background: Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist after the acute effects of the substance have subsided. These transient effects, sometimes labeled as the ‘psychedelic afterglow’, have been suggested to be associated with enhanced effectiveness of psychotherapeutic interventions in the subacute period....